Gefitinib tablets 250mg/tablet, 30 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Interstitial lung disease (ILD): ILD occurs in patients taking LuciGefi. LuciGefi should be interrupted if respiratory symptoms worsen. If ILD is confirmed, LuciGefi should be discontinued.
• Hepatotoxicity: Regular liver function testing. The use of LuciGefi should be suspended if the Alt and/or AST level rises to grade 2 or higher. In case of severe hepatic impairment, discontinue.
• Gastrointestinal perforation: In case of gastrointestinal perforation, LuciGefi should be discontinued.
• Diarrhoea: In case of grade 3 or higher diarrhoea, LuciGefi should be interrupted.
• Eye diseases (including keratitis): In case of signs and symptoms of serious or worsening eye diseases (including keratitis), the use of LuciGefi should be suspended. In case of persistent ulcerative keratitis, discontinue.
• Bullous and exfoliative dermatoses: In case of grade 3 or higher skin reaction or exfoliative disorders, the use of LuciGefi should be suspended.
• Embryo-fetal toxicity: May cause harm to the fetus. It is recommended to be aware of potential risks to the fetus and to use effective contraception.

Medication risks

Adverse Reactions
The most common adverse drug reactions (ADRs) were reported in more than 20% of patients and were more frequent than in the placebo group, i.e., skin reactions and diarrhea.